文献速递水电解质与酸碱急性肾损伤

甲氧苄啶-磺胺甲噁唑与高钾血症住院就诊风险:一项匹配的人群队列研究

Trimethoprim-sulfamethoxazole and the risk of a hospital encounter with hyperkalemia: a matched population-based cohort study.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

在加拿大安大略省≥66岁成人中,新用甲氧苄啶-磺胺甲噁唑(TMP-SMX)者较匹配的新用阿莫西林者,14天内高钾血症住院就诊风险更高(RR 3.36,95%CI 2.62-4.31),绝对风险随基线eGFR降低而递增,急性肾损伤和全因住院风险亦更高。

要点

  • TMP-SMX组高钾血症住院就诊269/58 999(0.46%),阿莫西林组80/58 999(0.14%),RR 3.36(95%CI 2.62-4.31)。
  • TMP-SMX较阿莫西林的高钾血症绝对风险差随eGFR降低而增大:eGFR≥60为0.12%,45-59为0.42%,30-44为0.85%,<30为1.45%(加性交互P<.001)。
  • TMP-SMX较阿莫西林急性肾损伤住院就诊RR 3.15(95%CI 2.82-3.51),全因住院RR 1.43(95%CI 1.34-1.53)。

核心结论

  • 新用TMP-SMX者14天内高钾血症住院就诊风险高于新用阿莫西林者,且基线eGFR越低风险越高。

研究设计与样本

  • 加拿大安大略省基于人群的匹配队列研究,纳入≥66岁新用TMP-SMX者58 999例,按1:1匹配新用阿莫西林者,研究期间为2008-2020年。

主要发现

  • TMP-SMX组高钾血症住院就诊269/58 999(0.46%),阿莫西林组80/58 999(0.14%),RR 3.36(95%CI 2.62-4.31)。
  • TMP-SMX较阿莫西林的高钾血症绝对风险差:eGFR≥60为0.12%,eGFR 45-59为0.42%,eGFR 30-44为0.85%,eGFR<30为1.45%(加性交互P<.001)。
  • TMP-SMX较阿莫西林急性肾损伤住院就诊RR 3.15(95%CI 2.82-3.51)。
  • TMP-SMX较阿莫西林全因住院RR 1.43(95%CI 1.34-1.53)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Trimethoprim-sulfamethoxazole (TMP-SMX) can cause hyperkalemia by reducing renal potassium excretion. We assessed the risk of hyperkalemia after initiating TMP-SMX versus amoxicillin and determined if this risk is modified by a patient's baseline kidney function [estimated glomerular filtration rate (eGFR)]. METHODS: We conducted a population-based cohort study in Ontario, Canada involving adults ≥66 years of age newly treated with TMP-SMX (n = 58 999) matched 1:1 with those newly treated with amoxicillin (2008-2020). The primary outcome was a hospital encounter with hyperkalemia defined by a laboratory serum potassium value ≥5.5 mmol/L within 14 days of antibiotic treatment. Secondary outcomes included a hospital encounter with acute kidney injury (AKI) and all-cause hospitalization. Risk ratios (RRs) were obtained using a modified Poisson regression. RESULTS: A hospital encounter with hyperkalemia occurred in 269/58 999 (0.46%) patients treated with TMP-SMX versus 80/58 999 (0.14%) in those treated with amoxicillin {RR 3.36 [95% confidence interval (CI) 2.62-4.31]}. The absolute risk of hyperkalemia in patients treated with TMP-SMX versus amoxicillin increased progressively with decreasing eGFR (risk difference of 0.12% for an eGFR ≥60 ml/min/1.73 m2, 0.42% for eGFR 45-59, 0.85% for eGFR 30-44 and 1.45% for eGFR <30; additive interaction P < .001). TMP-SMX versus amoxicillin was associated with a higher risk of a hospital encounter with AKI [RR 3.15 (95% CI 2.82-3.51)] and all-cause hospitalization [RR 1.43 (95% CI 1.34-1.53)]. CONCLUSIONS: The 14-day risk of a hospital encounter with hyperkalemia was higher in patients newly treated with TMP-SMX versus amoxicillin and the risk was highest in patients with a low eGFR.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Hwang YJ, Muanda FT, McArthur E, et al. Trimethoprim-sulfamethoxazole and the risk of a hospital encounter with hyperkalemia: a matched population-based cohort study. Nephrol Dial Transplant. 2023. PMID: 36208171. doi:10.1093/ndt/gfac282

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。